Crinetics Pharmaceuticals Releases ENDO 2024 Early Abstracts

Crinetics Pharmaceuticals, Inc., a San Diego-based clinical stage pharmaceutical firm listed on Nasdaq under the ticker symbol CRNX, has made a significant announcement. The company, which is dedicated to the discovery, development, and commercialization of innovative treatments for endocrine diseases and endocrine-related tumors, revealed that late-breaking abstracts for the Endocrine Society’s annual meeting (ENDO 2024) were released ahead of the previously scheduled embargo date.

Among the abstracts is a summary of data from a Phase 2, open-label study of atumelnant (CRN04894) in patients with Congenital Adrenal Hyperplasia (CAH). Initially, the abstract included data from four subjects. However, Crinetics intends to present more comprehensive data, encompassing six subjects from cohort 1 and additional subjects from cohort 2, at the ENDO 2024 event. The details will be shared during the Late-Breaking Poster Presentation session on June 3, 2024, from 12:00 to 1:30 pm ET.

Crinetics Pharmaceuticals is at the forefront of developing novel endocrine therapies. One of its leading investigational drugs, paltusotine, is an oral somatostatin receptor type 2 (SST2) agonist. This first-in-class drug is currently in Phase 3 trials for the treatment of acromegaly and in Phase 2 trials for managing carcinoid syndrome related to neuroendocrine tumors.

Another key candidate in Crinetics' pipeline is atumelnant (CRN04894), an oral ACTH antagonist. This drug is undergoing Phase 2 clinical trials aimed at treating congenital adrenal hyperplasia and Cushing’s disease. The company's pipeline also includes multiple other innovative, orally administered, small molecule drugs resulting from their in-house drug discovery efforts. These efforts target a range of endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes, and obesity.

In summary, Crinetics Pharmaceuticals is poised to make significant contributions to the treatment of endocrine diseases through its robust pipeline of investigational drugs, including paltusotine and atumelnant. The upcoming detailed presentations at ENDO 2024 promise to provide deeper insights into the efficacy and safety of atumelnant for Congenital Adrenal Hyperplasia, potentially paving the way for new therapeutic options for patients suffering from this condition.